Europe
$103 million raised in Series E expansion, including a new U.S.-based institutional investor, brings total Series E proceeds to $303 million
SonoCloud ultrasound device for glioblastoma patients will be tested for first time at US clinical sites
ADL Bionatur Solutions announced the expansion of the production agreement with a long-standing client, a global science-based company active in nutrition, health and sustainable living.
The Luxembourg Institute of Health and IBBL join forces with 20 European partners as part of CARDIATEAM, an Innovative Medicines Initiative translational research project aiming to improve diagnosis and care of diabetic cardiomyopathy, a heart dysfunction caused by diabetes.
Karolinska Development’s portfolio company Dilafor AB, a drug development company focusing on the development of tafoxiparin for obstetric indications, has enrolled the first subject in its Phase 2b study with tafoxiparin in pregnant women planned for labor induction.
Cooperation focused on the joint development and optimization of human anti-infective drug candidates against gram-negative and gram-positive bacteria in relevant indications using Lysando’s Artilysin®s technology platform
Addex Therapeutics announced that it will lead a consortium for the development of small-molecule negative allosteric modulators targeting the metabotropic glutamate receptor 7 as a potential treatment to reduce fear memory in post-traumatic stress disorder.
Construction to host IBA’s Proteus®ONE system expected to start later this year
Kuros Biosciences announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a distribution agreement for the Australian and New Zealand healthcare markets with Surgical Specialties, a subsidiary of the Paragon Care Group, a leading provider of medical equipment, devices and consumables.
Patients with bowel cancer who have stopped responding to a widely used targeted drug could benefit from immunotherapy, a major new study reveals.
PRESS RELEASES